Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Infective Risk Reduction: GeneSoft Skips to the Clinic

This article was originally published in Start Up

Executive Summary

GeneSoft Inc., a company founded to commercialize technology for interfering with gene expression using compounds that bind to grooves on DNA sequences has a wide scope of potential applications before it, but it has chosen to position itself as an anti-infective specialty pharmaceuticals company. Its direction stems not merely from unpopularity of platform models, but because it believes it's learned the lessons of its in-licensing anti-infective forebears and can pursue the strategy with lower risk.

You may also be interested in...



GeneSoft: The Value of Compromised Products

Following the FDA's rejection of Factive, GlaxoSmithKline gave it back to its Korean owner, LG Life Sciences Now the compromised--and newly approved--product is the basis for a start-up's spectacular return from a near-death experience--and the latest in a string of biotech successes based around products the previous owners had rejected.

Cubist: The Virtues of Pipeline Diversification

Cubist, like other companies in the anti-infectives space, was founded on the assumption that anti-infective drugs entering the clinic had a significantly lower risk of failure than other therapeutics. That risk profile may be changing because of the FDA's imposition of stricter standards for the approval of anti-microbials. So far, Cubist has met that challenge with respect to daptomycin, the Phase III antibiotic that would be the company's first marketed product. Yet, a cloud of regulatory uncertainty still lingers. But through aggressive dealmaking, Cubist has built a discovery and development pipeline that helps to balance the risk that daptomycin may run into unexpected roadblocks on the way to approval.

Wound Solutions Ltd.

Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel